COSCIENS Biopharma Inc. (CSCIF)

COSCIENS Biopharma Inc. (CSCIF) Healthcare & Pipeline Overview

COSCIENS Biopharma Inc. is a Canadian life science company focused on developing and commercializing active ingredients for cosmeceutical and nutraceutical markets, alongside pharmaceutical products like Macrilen/Ghryvelin for growth hormone deficiency. Operating globally, it leverages a network of distribution partners and license agreements to address diverse healthcare and cosmetic needs.

What Is the Investment Thesis for CSCIF?

COSCIENS Biopharma Inc. presents a research profile centered on its dual-segment approach in active ingredients and pharmaceuticals, underpinned by a high gross margin of 95.1%. The company's value drivers include the commercialization of Macrilen/Ghryvelin for growth hormone deficiency diagnostics and its potential expansion into broader endocrinology and oncology indications. Growth catalysts are anticipated through the continued penetration of its active ingredients, such as oat beta glucan for cholesterol reduction and avenanthramides for inflammation, into the global cosmeceutical and nutraceutical markets. Strategic license agreements with partners like Pharmanovia and MegaPharm Ltd. provide established distribution channels, potentially enhancing market reach and revenue streams. However, the company's negative profit margin of -78.9% indicates ongoing operational losses, necessitating careful monitoring of its path to profitability. Its small market capitalization of $2.79M and trading on the OTC market introduce liquidity and disclosure risks. The company's beta of 1.47 suggests higher volatility compared to the broader market. Future growth depends on successful market adoption of existing products and potential pipeline advancements.

Based on FMP financials and quantitative analysis

CSCIF Key Highlights

• Gross Margin: 95.1%, indicating strong profitability on products sold before operating expenses.
• Profit Margin: -78.9%, reflecting significant operational losses despite high gross margins.
• Market Capitalization: $0.01 billion, classifying it as a micro-cap company.
• Beta: 1.47, suggesting higher volatility relative to the overall market.
• Global Reach: Products commercialized in the United States, Germany, Colombia, and the United Kingdom, leveraging a network of distribution partners.

Who Are CSCIF's Competitors?

CSCIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CSCIF's Key Strengths?

• High gross margin of 95.1% on product sales.
• Proprietary pharmaceutical product (Macrilen/Ghryvelin) with specific diagnostic indications.
• Diverse product portfolio spanning cosmeceutical, nutraceutical, and pharmaceutical markets.
• Established international distribution network and strategic licensing agreements.
• Focus on specialized, science-backed active ingredients.

What Are CSCIF's Weaknesses?

• Significant negative profit margin of -78.9%, indicating ongoing unprofitability.
• Small market capitalization ($0.01B) and limited employee base (40 employees).
• Reliance on license agreements for market reach, potentially limiting direct control over sales.
• Trading on the OTC market, which can entail lower liquidity and less stringent disclosure.

What Could Drive CSCIF Stock Higher?

• Potential expansion of Macrilen/Ghryvelin's approved indications into broader endocrinology or oncology markets, which could significantly increase its addressable patient population and revenue streams.
• Announcement of new strategic licensing or distribution agreements for Macrilen/Ghryvelin or its active ingredients in previously untapped international markets.
• Continued commercialization and market penetration of its active ingredients (oat beta glucan, yeast beta glucan, avenanthramides) within the growing global cosmeceutical and nutraceutical sectors.
• Publication of clinical data or regulatory milestones related to Macrilen/Ghryvelin's potential for new indications, supporting its expanded use.
• Efforts to improve financial performance and move towards profitability, potentially through cost efficiencies or increased sales volume.

What Are the Key Risks for CSCIF?

• Financial-distress signal — its Altman Z-Score of 0.74 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-13.2%) — the business is not currently generating profit on shareholder capital.
• Persistent negative profit margin of -78.9%, indicating a lack of profitability and ongoing operational losses that could impact long-term sustainability.
• High competition within the biotechnology, cosmeceutical, and nutraceutical markets from larger, more established companies with greater resources.
• Risks associated with trading on the OTC "Other" tier, including low liquidity, potential for wide bid-ask spreads, and limited public disclosure, which can affect investor confidence and trading efficiency.
• Regulatory hurdles and delays in obtaining approvals for new indications for Macrilen/Ghryvelin or for any new products in its pipeline, impacting market entry and revenue generation.
• Dependence on key license agreements and distribution partners for market access, where changes in these relationships could disrupt sales and commercialization efforts.

What Are the Growth Opportunities for CSCIF?

• Expansion of Macrilen/Ghryvelin Indications and Markets: Macrilen/Ghryvelin (macimorelin) is currently approved for diagnosing adult and childhood-onset growth hormone deficiency. A significant growth opportunity lies in pursuing additional endocrinology and oncology indications, as mentioned in the company description. Expanding the approved uses for this orally available ghrelin receptor agonist could unlock access to larger patient populations and new therapeutic markets. The global market for growth hormone deficiency treatments and diagnostics is substantial, and securing additional indications would allow COSCIENS Biopharma Inc. to capture a larger share, potentially increasing its revenue streams over the next 3-5 years.
• Increased Penetration in Cosmeceutical and Nutraceutical Markets: COSCIENS Biopharma Inc.'s active ingredients, such as oat beta glucan for cholesterol reduction, yeast beta glucan for immune boosting, and avenanthramides for inflammation, target the rapidly expanding cosmeceutical and nutraceutical markets. The global nutraceutical market alone is projected to reach hundreds of billions of dollars in the coming years, driven by consumer demand for natural and functional ingredients. By enhancing its distribution network and forging new partnerships, the company can increase the adoption of these ingredients by other manufacturers, securing a larger footprint in these health and beauty segments over the medium term (2-4 years).
• Leveraging and Expanding License Agreements: The company has established license agreements with several partners, including Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd. These agreements provide critical distribution channels and market access in various international regions. A key growth opportunity involves maximizing the potential of these existing partnerships by supporting their sales and marketing efforts, and exploring new licensing opportunities in untapped geographic markets or for additional product applications. Strengthening these alliances can lead to expanded market reach and increased royalty or sales-based revenues within the next 1-3 years.
• Research and Development of New Active Ingredients: Building upon its expertise in natural compounds, COSCIENS Biopharma Inc. has an opportunity to invest in the research and development of novel active ingredients for its cosmeceutical and nutraceutical segments. The market continually seeks innovative, science-backed ingredients for anti-aging, wellness, and specific health concerns. By identifying and developing new compounds, potentially leveraging its relationships with institutions like Agriculture Canada and the University of Alberta, the company could introduce proprietary ingredients that command premium pricing and establish new revenue streams, with a development timeline typically spanning 3-7 years.
• Geographic Market Expansion: While COSCIENS Biopharma Inc. has an international presence in the United States, Germany, Colombia, and the United Kingdom, there are numerous other global markets with significant demand for biotechnology products, specialized pharmaceuticals, and active ingredients. Expanding its distribution network and securing new regulatory approvals or licensing partners in high-growth regions, particularly in emerging economies or underserved developed markets, represents a substantial growth avenue. This strategic expansion could involve targeted market entry for Macrilen/Ghryvelin or its active ingredients, potentially diversifying revenue sources over a 3-5 year horizon.

What Opportunities Does CSCIF Have?

• Expansion of Macrilen/Ghryvelin into additional endocrinology and oncology indications.
• Increased market penetration for active ingredients in growing cosmeceutical and nutraceutical sectors.
• Formation of new strategic partnerships and licensing agreements for broader geographic reach.
• Development of new proprietary active ingredients or pharmaceutical compounds.
• Capitalization on increasing global demand for natural health products and specialized diagnostics.

What Threats Does CSCIF Face?

• Intense competition from larger pharmaceutical and biotech companies.
• Regulatory challenges and potential delays in securing approvals for new indications or products.
• Market acceptance and adoption risks for both active ingredients and pharmaceutical products.
• Economic downturns impacting consumer spending on cosmeceuticals and nutraceuticals.
• Operational risks associated with a small company managing global distribution and multiple product lines.

What Are CSCIF's Competitive Advantages?

• Proprietary pharmaceutical product, Macrilen/Ghryvelin, with specific indications for growth hormone deficiency diagnostics.
• Specialized portfolio of active ingredients derived from natural sources, such as oat and yeast beta glucan, and avenanthramides.
• Established international distribution network and strategic license agreements providing market access in key regions.
• License agreements with research institutions like Agriculture Canada and the University of Alberta, potentially providing access to intellectual property or research capabilities.
• Expertise in developing and commercializing products across three distinct but related markets: cosmeceutical, nutraceutical, and pharmaceutical.

What Does CSCIF Do?

COSCIENS Biopharma Inc., headquartered in Toronto, Canada, is a life science company with a history dating back to its incorporation in 1990. Initially known as Aeterna Zentaris Inc., the company underwent a significant rebranding, changing its name to COSCIENS Biopharma Inc. in August 2024. This evolution reflects its strategic focus on developing and commercializing specialized products across the cosmeceutical, nutraceutical, and pharmaceutical sectors. The company operates through two primary segments: Active Ingredient and Pharmaceutical. In its Active Ingredient segment, COSCIENS Biopharma Inc. develops and supplies a range of specialized compounds. These include oat beta glucan, formulated as a chewable product aimed at cholesterol reduction, and beta glucan derived from yeast, offered as a nutraceutical capsule designed to function as an immune booster. Additionally, the company provides avenanthramides, a nutraceutical chewable formulation recognized for its anti-inflammatory properties, serving both the healthcare and cosmetic industries. These ingredients underscore the company's commitment to leveraging natural compounds for health and wellness applications. The Pharmaceutical segment is anchored by Macrilen/Ghryvelin (macimorelin), a key product in COSCIENS Biopharma Inc.'s portfolio. Macimorelin is an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist. Its mechanism of action involves stimulating the secretion of growth hormone by binding to the GHSR-1a, making it a critical diagnostic tool. It is indicated for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency. Beyond diagnostics, Macrilen/Ghryvelin holds potential for broader applications within endocrinology and oncology indications, representing a significant asset for the company. COSCIENS Biopharma Inc. maintains an international presence, with commercial activities spanning the United States, Germany, Colombia, and the United Kingdom, among other global markets. The company distributes its products through an established network and has cultivated strategic license agreements with various partners, including Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd. Furthermore, it holds foundational license agreements with research institutions such as Agriculture Canada and the University of Alberta, which likely support its innovation and product development pipeline. With 40 employees, COSCIENS Biopharma Inc. focuses on specialized market niches within the broader life sciences landscape.

What Products and Services Does CSCIF Offer?

• Develops and commercializes active ingredients for the cosmeceutical and nutraceutical industries.
• Offers oat beta glucan chewables for cholesterol reduction.
• Provides yeast beta glucan capsules for immune boosting.
• Supplies avenanthramides, a chewable formulation for inflammation reduction.
• Develops and commercializes Macrilen/Ghryvelin (macimorelin) for diagnosing adult and childhood growth hormone deficiency.
• Explores Macrilen/Ghryvelin applications in broader endocrinology and oncology indications.
• Sells products internationally through a distribution network.
• Holds license agreements with various pharmaceutical distributors and research institutions.

How Does CSCIF Make Money?

• Generates revenue through the sale of proprietary active ingredients to healthcare and cosmetic industries.
• Monetizes its pharmaceutical product, Macrilen/Ghryvelin, through direct sales or licensing agreements for diagnostic use.
• Leverages a global distribution network to reach markets in the US, Germany, UK, and Colombia.
• Engages in licensing agreements with pharmaceutical companies for commercialization rights in specific territories.
• Collaborates with research institutions for technology and product development.

What Industry Does CSCIF Operate In?

COSCIENS Biopharma Inc. operates within the dynamic Healthcare sector, specifically positioned in the Biotechnology industry. This industry is characterized by intensive research and development, stringent regulatory pathways, and a focus on innovative biological products and therapies. The company differentiates itself by straddling two distinct, yet complementary, areas: the development of active ingredients for the cosmeceutical and nutraceutical markets, and specialized pharmaceutical products. The global nutraceutical market, for instance, is experiencing robust growth driven by increasing consumer awareness of health and wellness, while the pharmaceutical market for rare diseases and specialized diagnostics continues to expand. COSCIENS Biopharma Inc.'s Macrilen/Ghryvelin targets a niche within endocrinology, a segment with specific diagnostic needs. Its active ingredients compete in a fragmented market with numerous players, but its focus on specific compounds like oat beta glucan and avenanthramides allows for targeted market penetration. The company's competitive landscape includes larger pharmaceutical companies with broader pipelines and smaller biotech firms specializing in similar active ingredients or diagnostic tools.

Who Are CSCIF's Key Customers?

• Pharmaceutical companies seeking diagnostic tools for growth hormone deficiency.
• Cosmeceutical manufacturers requiring active ingredients for skincare and beauty products.
• Nutraceutical companies formulating dietary supplements for cholesterol, immunity, and inflammation.
• Healthcare providers and endocrinologists utilizing Macrilen/Ghryvelin for patient diagnosis.
• International distributors who market and sell the company's products in various regions.

Company Profile

COSCIENS Biopharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Peter Harry Puccetti. CSCIF has traded publicly since 2000.

COSCIENS Biopharma Inc. Financial Trajectory

COSCIENS Biopharma Inc. (CSCIF) reported $1.9M in revenue for Q1 2026, reflecting 3.9% growth compared to the prior quarter. The company recorded a net loss of $529K, with diluted EPS of $-0.17. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, CSCIF averaged $-0.57 in diluted EPS.

How COSCIENS Biopharma Inc. Is Valued

COSCIENS Biopharma Inc. carries a market capitalization of $2.79M, placing it in the micro-cap category. Relative to its peer group, CSCIF's quantitative score of 62/100 is below the peer average of 76/100.

ROE -13%Key Financial Metrics

Return on equity for COSCIENS Biopharma Inc. stands at -13.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.6%, showing how much profit it generates from its asset base. A current ratio of 8.01 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -37.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

COSCIENS Biopharma Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.74 places it in the distress zone, a signal of elevated financial risk.

CSCIF Financials

CSCIF Latest News

No recent news available for CSCIF.

CSCIF Analyst Consensus

CSCIF MoonshotScore

Common Questions About CSCIF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources